Press releases
-
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
ICON plc today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding.
-
ICON plc to present at the 42nd annual J.P. Morgan Healthcare conference
ICON plc today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST.
-
ICON wins industry accolades from TIME Magazine, Forbes and Financial Times in second half of 2023
ICON plc finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.
-
ICON secures upgraded credit rating from Moody’s Investors Service
Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook. This reflects the stronger credit profile of the ICON Group, which Moody’s now views as comparable in aggregate to Baa3 peers.
-
ICON plc to present at upcoming investor conferences
ICON plc today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 2:00pm GMT. Mr. Brendan Brennan will also present at the Evercore HealthCONx Conference on Wednesday, November 29, 2023, at 12:30pm ET.
-
ICON reports third quarter 2023 results
Quarter three revenue of $2,055.1 million representing an increase of 5.8% on prior year revenue.
-
ICON secures upgraded credit rating from S&P Global Ratings
ICON plc today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.
-
ICON schedules third quarter 2023 earnings conference call
ICON plc announced that it will release its financial results for the third quarter 2023 after the market closes on Wednesday, October 25, 2023.
-
ICON releases expanded end-to-end Clinical Trial Tokenisation solution
ICON announces the release of its next generation Clinical Trial Tokenisation solution.
-
BARDA partners with ICON to execute next generation COVID-19 vaccines clinical trial
ICON plc today announces that it is partnering with BARDA to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates.
